09:27 | 07/10/2019 Companies
(VEN) - One of the first healthcare companies to establish a presence in Vietnam, GSK (with headquarter in the UK) has grown to become one of the biggest companies in the country in this sector.
|Dan Millard, Chief Representative, GSK Vietnam|
“In the past 25 years, we have been tireless in our efforts to work alongside the healthcare sectors and healthcare professionals to prevent and treat diseases in Vietnam, helping Vietnamese people to do more, feel better and live longer,” said Dan Millard, Chief Representative of GSK Vietnam.
Today, GSK has all its 3 core areas here in Vietnam: medicines, vaccines and consumer healthcare products. They have invested heavily in global R&D and introduced innovative solutions that meet Vietnam’s disease patterns, ensuring patients have better access to essential medicines and vaccines.
They continuously support health-care professionals to update treatment guidelines as well as medical practices around the world, educate patients about the burden of disease as well as the importance of early prevention and adherence to treatment.
“Recently, recognizing that the ways in which HCPs consume information is changing in the digital age, we have expanded the choices of engagement channels that help hundreds and thousands of doctors and pharmacists nationwide to access updated treatment information and worldwide best medical practices faster and more conveniently than ever before.” Millard said.
GSK has also helped build capabilities of local partners by conducting various clinical trials in Vietnam as part of a global medicines developing program.
The company has also awarded PATH Vietnam, an international non-governmental organization, a significant grant to support the implement the health ministry’s Immunization Management System.
“Ultimately, for GSK, the patient is our first priority, and every employee in the company is motivated to see that millions of patients have been treated with our medicines for acute infectious diseases and chronic respiratory diseases and more than 1 million complete courses of vaccines have been given to Vietnamese children in 2018 alone” Millard said.
Vietnam’s pharma progress
He also said that Vietnam was a rapidly developing and hugely exciting place to do business with increasing efforts to open up the market to global trade.
The efforts to align with many global standards, practices, and regulations is reflected in the 2016 Pharma law and its following Decrees and Circulars, he stressed.
“This will support faster and more stable access for patients to new and high-quality vaccines and medicines such as faster registration process, improved importation process for innovative medicines, and vaccines prequalified by WHO, and so on.
“It will also help foreign investors prioritize local manufacturing partnerships.
“It is exciting to see the progress Vietnam has made over the past two decades with its Universal Healthcare Coverage. The country has been ambitious and continues to target national coverage of at least 90 percent by 2020 and 95 percent by 2025”, Millard noted.
He assessed that Vietnam continues to be an attractive FDI destination in ASEAN, with exciting, young, passionate and positive energy, high commitment and can-do attitude.
The country has a rapidly expanding middle class, with an increased awareness of healthcare and a growing demand for quality healthcare products and services in Vietnam. Hence, Vietnam has the potential to become more attractive for foreign pharmaceutical companies in general and British companies in particular. Plans for Vietnam
“Our goal is to become one of the most innovative, best performing and trusted companies in the world. In Vietnam, GSK mission and top priority is to provide sufficient, quality vaccines and pharmaceuticals to match Vietnam’s disease patterns, meet the needs of healthcare professionals and patients and ensure it is accessible and available.
“Besides this, our efforts are continuously focused on providing innovative solutions to solve healthcare challenges. Examples include using antibiotics appropriately to tackle anti-microbial resistance, managing non-communicable diseases like asthma and COPD, enhancing public awareness on the burden of infectious diseases, as well as increasing immunization coverage to create a healthy community for Vietnam,” Millard said.
“We are also working closely with the MOH to explore the opportunity to set up a Foreign Investment Enterprise (FIE) in Vietnam in a long-term” Millard said.
GSK’s CSR activities in Vietnam
Globally, GSK and Save the Children have launched a five-year partnership to help the most vulnerable children. In Vietnam, GSK and Save the Children have co-organized a healthcare project for mothers and newborns of ethnic minorities in the northern region that aims at training health workers, improving newborn care units, and establishing Kangaroo Mother Care Units at the localities to improve access to mother-and-newborn healthcare services at grassroots level medical stations. The project also focuses on educating and raising public awareness on mother-and-newborn healthcare, thus boosting the needs for local healthcare services and increasing access to basic health care.
GSK has awarded PATH Vietnam a significant grant to support implementation of Ministry of Health’s Immunization Management System. It has also instituted an award to honour innovative ideas that successfully reduce childhood mortality rates in developing countries. This has enhanced national immunization coverage at the grassroots level. So far 63 provinces have been set up the National Immunization Information System and 10 million people have been registered in it. The system helps healthcare professionals track infants and pregnant women due for vaccinations, reduce time required for recording and reporting immunization data and ensure quality and availability of vaccines.